Anti-seizure Medication Prescription in Adult Outpatients With Epilepsy in China, 2013–2018

摘要: This study aimed to assess the national trends in ASM prescribing Chinese adult outpatients with epilepsy over a 6-year period from 2013 2018. Prescriptions for hospitals six major cities were extracted database of Hospital Prescription Analysis Cooperative Project. Trends annual prescriptions and expenditure analyzed. Prescribing patterns (monotherapy or combination therapy) also assessed. A total 225,767 60 eligible analysis. The number increased 28,360 44,110 2018, corresponding cost 9,452,990 Yuan (CNY) 14,627,865 CNY share newer use continuously, accounting 56.75% 85.03% most frequently prescribed ASMs sodium valproate levetiracetam. proportion decreased, while levetiracetam dramatically both terms expenditure. Monotherapy was more frequent than therapy. three common therapies valproate/lamotrigine, levetiracetam/oxcarbazepine, valproate/levetiracetam. In summary, rapidly during period, which raises concern regarding rational pharma-economic profiles ASMs. place valproate, became used ASM. development is line therapy guidelines reflects current state research China.